Navigation Links
DoctorDirectory to Co-market VoSpire ER(R) with DAVA Pharmaceuticals, Inc.
Date:7/29/2008

ASHEVILLE, N.C., July 29 /PRNewswire/ -- DoctorDirectory.com, Inc. announced that it is partnering with DAVA Pharmaceuticals, Inc. to co-market VoSpire ER(R) (Albuterol Sulfate) Extended-Release Tablets through its IncreaseRx(R) virtual marketing solution. IncreaseRx utilizes web-based educational and promotional tactics to reach tens of thousands of interested prescribers with targeted sales and marketing messages. Essentially, IncreaseRx performs as a virtual contract sales organization providing e-sampling and online educational tools. "Our team is looking forward to promoting VoSpire ER(R) with DAVA. Albuterol sulfate remains a standard of long-lasting oral therapy for patients," said Jay Grobowsky, CEO for DoctorDirectory.

VoSpire ER(R) is indicated for the relief of bronchospasm in adults and children 6 years of age and older with reversible obstructive airway disease.

"We at DAVA felt that the DoctorDirectory team and the IncreaseRx solution were an excellent fit for the continued promotion of VoSpire ER(R). The strength of IncreaseRx is in its ability to reach far more prescribers than we could have by utilizing a traditional sales force model. The value-based relationship that DoctorDirectory has with its physicians gives our brand a particularly attractive solution," said Liad Spiro, Senior Director, Commercialization and Marketing for DAVA.

DoctorDirectory is a marketing solutions company that specializes in providing brand teams and their agencies web-based access to Healthcare Professionals. IncreaseRx is a whitespace strategy designed to reach under-performing or inaccessible physician segments and generate incremental revenue from unrealized potential. It utilizes a suite of traditional and web-based tactics to generate incremental revenue for any pharma brand regardless of product life cycle.

For more information about DoctorDirectory or IncreaseRx, contact Jay Grobowsky at 828-255-0252 or by email at jay.grobowsky@doctordirectory.com.

DAVA Pharmaceuticals, Inc. is a global pharmaceutical company committed to providing cost-effective pharmaceutical products to the healthcare market by integrating expertise in product development, manufacturing and marketing with global strategic alliances to deliver medicines from the source.

For more information about DAVA Pharmaceuticals, Inc., contact Liad Spiro at 201-947-7442 or by email at LSpiro@davapharma.com.

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE DoctorDirectory.com, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. XCPT(TM) Patient Engagement and Communication Software and DentalXP.com, a Leading Provider of Online Dental Education and Content, Sign a Co-Marketing Agreement
2. Energizer Joins Roster of Susan G. Komen Race for the Cure(R) National Sponsors; Energizer(R) ReTreat Pampers Cancer Survivors With Traveling Mini-Spa
3. Infor-Med, Inc. Announces New Praxis EMR Version 4 with The Praxis Knowledge Exchanger(R)
4. Manhattan Research: ePharma Consumer(R) Research and Advisory Service Now Available
5. FDA Approves ASMANEX (R) TWISTHALER(R) (Mometasone Furoate Inhalation Powder) for the Once Daily Maintenance Treatment of Asthma in Children Ages 4-11
6. Nano Pet Products, LLC Named Exclusive Worldwide Licensee by Schoeller(R) Technologies AG for Pet Products to Develop the Most Technologically Advanced Pet Brands on the Market Today
7. Pioneer(R) Surgical Technology, Inc. Continues to Prove Science Behind PEEK-on-PEEK(TM) Technology for Motion Preservation Devices
8. Quaker(R) Life(R) Cereal Partners with Actress and Mom Holly Robinson Peete to Inspire Moms to Make Their Best Days Happen
9. Kinetic Technologies, Makers of Conquer(R), Introduces New Website
10. CAS New SciFinder(R) Enhances the Research Experience Via the Web
11. AGA Medical Corporation Receives CE Mark Approval for the AMPLATZER(R) Vascular Plug III
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2016)... (PRWEB) , ... April 30, 2016 , ... “Aging well is a challenge for all of us, but there are ... Dr. Parul T. Kohli . “Research is showing more and more that there are simple, ... disease and disability as we age.” Top priorities Dr. Kohli’s recommends for her patients include;, ...
(Date:4/29/2016)... Dobbs Ferry, New York (PRWEB) , ... April 30, 2016 , ... ... and the Dobbs Ferry campus. The following programs will be expanding due to ... Resources Management (HRM). The expansion will begin this summer. , School ...
(Date:4/29/2016)... Hollywood, Fl (PRWEB) , ... April 29, 2016 ... ... was recently notified by the Accreditation Council for Graduate Medical Education (ACGME) that ... , This is the first accreditation of three residency programs that Memorial ...
(Date:4/29/2016)... Atlanta, Georgia (PRWEB) , ... April 29, 2016 , ... ... 60 rural hospitals across the Southeast, celebrated the signature of Gov. Nathan Deal on ... by Rep. Geoff Duncan (R - Cumming), offers a 70% tax credit to individuals ...
(Date:4/29/2016)... ... 2016 , ... The White House announced efforts yesterday to ... about their loan terms and accounts, and more protections for borrowers. The announcement ... private loans, has reached $1.3 trillion, with 43 million Americans holding student loans ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016 Dr. ... and Ste phen ... ArisGlobal®, a leading provider of cloud-based software solutions for life ... Pharmacovigilance team to bring a wealth of insight to a growing ... pharmacovigilance knowledge. George Phillips joined ArisGlobal in ...
(Date:4/28/2016)... , April 28, 2016  ValGenesis, Inc., ... Management Solutions (VLMS) today announced that a ... for sufferers of chronic kidney failure has ... manage their corporate validation process. The global ... software solution to manage their validation processes ...
(Date:4/27/2016)... 2016  Hologic, Inc. (Nasdaq: HOLX ... the fiscal second quarter ended March 26, 2016.  ... increased 41.2%, and non-GAAP diluted EPS of $0.47 ... on a reported basis, and 6.3% on a ... another good quarter, highlighted by 14.6% growth in ...
Breaking Medicine Technology: